These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 11125883)

  • 21. Implications of Immune Checkpoint Expression During Aging in HIV-Infected People on Antiretroviral Therapy.
    de Armas LR; Pallikkuth S; Rinaldi S; Pahwa R; Pahwa S
    AIDS Res Hum Retroviruses; 2019; 35(11-12):1112-1122. PubMed ID: 31578868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
    Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
    AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNA-electroporated CD40-activated autologous B-cells.
    Van den Bosch GA; Van Gulck E; Ponsaerts P; Nijs G; Lenjou M; Apers L; Kint I; Heyndrickx L; Vanham G; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
    J Immunother; 2006; 29(5):512-23. PubMed ID: 16971807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study on immunological status of Chinese HIV-infected individuals.
    Shang H; Jiang Y; Zhang Z; Han X; Zhang M; Wang Y; Liu J
    Microbiol Immunol; 2004; 48(11):883-8. PubMed ID: 15557746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct ex vivo analysis reveals distinct phenotypic patterns of HIV-specific CD8(+) T lymphocyte activation in response to therapeutic manipulation of virus load.
    Oxenius A; Günthard HF; Hirschel B; Fidler S; Weber JN; Easterbrook PJ; Bell JI; Phillips RE; Price DA
    Eur J Immunol; 2001 Apr; 31(4):1115-21. PubMed ID: 11298336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy - CTN PT006: study protocol for a randomized controlled trial.
    Lebouché B; Jenabian MA; Singer J; Graziani GM; Engler K; Trottier B; Thomas R; Brouillette MJ; Routy JP
    Trials; 2014 Oct; 15():390. PubMed ID: 25293882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiretroviral therapy-induced dominant interleukin-2 HIV-1 Gag CD4+ T cell response: evidence of functional recovery of HIV-1-specific CD4+ T cells.
    Tsalimalma K; Kordossis T; Choremi-Papadopoulou E
    Scand J Immunol; 2011 Mar; 73(3):256-65. PubMed ID: 21204901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.
    Kaiser P; Joos B; Niederöst B; Weber R; Günthard HF; Fischer M
    J Virol; 2007 Sep; 81(18):9693-706. PubMed ID: 17609262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of antiretroviral and tuberculosis therapies on CD4
    Chiacchio T; Petruccioli E; Vanini V; Cuzzi G; La Manna MP; Orlando V; Pinnetti C; Sampaolesi A; Antinori A; Caccamo N; Goletti D
    Immunol Lett; 2018 Jun; 198():33-43. PubMed ID: 29635002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative and qualitative assessment of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cell immunity to gag in HIV-1-infected individuals with differential disease progression: reciprocal interferon-gamma and interleukin-10 responses.
    Ostrowski MA; Gu JX; Kovacs C; Freedman J; Luscher MA; MacDonald KS
    J Infect Dis; 2001 Nov; 184(10):1268-78. PubMed ID: 11679915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
    Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
    Piriou E; Jansen CA; van Dort K; De Cuyper I; Nanlohy NM; Lange JM; van Oers MH; Miedema F; van Baarle D
    J Immunol; 2005 Aug; 175(3):2010-7. PubMed ID: 16034146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy.
    Valor L; Navarro J; Carbone J; Rodríguez-Sáinz C; Gil J; López F; Fernández-Cruz E;
    Vaccine; 2008 May; 26(22):2738-45. PubMed ID: 18433946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.
    Chun TW; Justement JS; Moir S; Hallahan CW; Ehler LA; Liu S; McLaughlin M; Dybul M; Mican JM; Fauci AS
    Proc Natl Acad Sci U S A; 2001 Jan; 98(1):253-8. PubMed ID: 11136258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlates of antiviral immune restoration in acute and chronic HIV type 1 infection: sustained viral suppression and normalization of T cell subsets.
    Dyer WB; Kuipers H; Coolen MW; Geczy AF; Forrester J; Workman C; Sullivan JS
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):999-1010. PubMed ID: 12396452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease.
    Carmichael A; Jin X; Sissons P; Borysiewicz L
    J Exp Med; 1993 Feb; 177(2):249-56. PubMed ID: 8093890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T-cell signalling in antiretroviral-treated, aviraemic HIV-1-positive individuals is present in a raised state of basal activation that contributes to T-cell hyporesponsiveness.
    Downey JS; Attaf M; Moyle G; Gazzard B; Gotch F; Imami N
    AIDS; 2011 Oct; 25(16):1981-6. PubMed ID: 21811141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of HIV-1 Gag-specific T cell responses in chronically infected Indian population.
    Kaushik S; Vajpayee M; Wig N; Seth P
    Clin Exp Immunol; 2005 Nov; 142(2):388-97. PubMed ID: 16232229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.